Morgan Stanley
NRSN icon

Morgan Stanley’s NeuroSense Therapeutics NRSN Stock Holding History

Morgan Stanley’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,320
Closed -$83K – 8387
2025
Q3 		$83K Sell
3,320
-675
-17% -$19.8K ﹤0.01% 6236
2025
Q2 		$151K Buy
3,995
+1,470
+58% +$42.6K ﹤0.01% 5961
2025
Q1 		$47K Sell
2,525
-2,604
-51% -$57.6K ﹤0.01% 6292
2024
Q4 		$123K Buy
+5,129
New +$118K ﹤0.01% 5975
2024
Q3 		– Sell
-75
Closed -$1.68K – 7997
2024
Q2 		$1.68K Hold
75
– – ﹤0.01% 7089
2024
Q1 		$2.73K Hold
75
– – ﹤0.01% 7019
2023
Q4 		$1.18K Buy
+75
New +$997 ﹤0.01% 7117
2023
Q1 		– Hold
0
– -$5 – 7796
2022
Q4 		– Hold
0
– – – 7832
2022
Q3 		– Hold
0
– – – 7819

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Morgan Stanley's NRSN Position: Q4 2025 in Review

Morgan Stanley sold out of NeuroSense Therapeutics (NRSN) in Q4 2025, closing a stake of 3,320 shares — an estimated $83K sold.

Morgan Stanley first reported a position in NRSN in Q4 2023 and held it in 7 quarters. The position peaked at $151K in Q2 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q4 2025.

  • Morgan Stanley reported no remaining NeuroSense Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 3,320 NeuroSense Therapeutics shares in Q4 2025, an estimated $83K.
  • Morgan Stanley first reported a position in NeuroSense Therapeutics in Q4 2023 and held it in 7 quarters.
  • Morgan Stanley's NeuroSense Therapeutics position peaked at $151K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.